Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is used to treat idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adult patients, helping to slow disease progression and preserve lung function.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is an antifibrotic agent that targets progressive fibrosing lung disorders.

- Idiopathic pulmonary fibrosis: slows the decline in forced vital capacity and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: limits worsening of lung fibrosis and improves functional outcomes. - Progressive fibrosing interstitial lung disease (PF‑ILD): may delay overall disease progression in eligible patients.

Nintedanib may cause a range of adverse reactions, from mild to serious. Patients should be monitored regularly for any new symptoms.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may occur with or without vomiting. - Abdominal pain: discomfort or cramps in the stomach area. - Decreased appetite: reduced desire to eat, potentially leading to weight loss. - Vomiting: expulsion of stomach contents, usually intermittent.

Serious or Rare Side Effects: - Elevated liver enzymes: indicates possible liver injury, requires laboratory monitoring. - Bleeding events: increased risk of gastrointestinal or other bleeding, especially with anticoagulants. - Cardiovascular complications: such as hypertension or arterial thrombotic events. - Severe infections: opportunistic infections may arise in immunocompromised patients. - Gastrointestinal perforation: rare but serious condition requiring immediate medical attention.

Before initiating therapy, clinicians should assess individual risk factors and monitor patients throughout treatment.

- Liver function monitoring: obtain baseline and periodic liver enzyme tests. - Bleeding risk assessment: evaluate concomitant anticoagulant or antiplatelet use. - Cardiovascular evaluation: screen for hypertension or history of thrombotic events. - Renal function review: adjust use in patients with significant renal impairment. - Drug interaction review: check for concomitant medications that may affect metabolism. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Nintedanib can interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive bleeding potential.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for gastrointestinal bleeding. - Diuretics: watch for changes in fluid balance and blood pressure.